MedPath

Essentialis, Inc.

🇺🇸United States
Ownership
Subsidiary
Established
2017-01-01
Employees
1
Market Cap
-
Website
http://essentialistherapeutics.com

Clinical Trials

8

Active:0
Completed:5

Trial Phases

3 Phases

Phase 1:4
Phase 2:3
Phase 3:1

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (8 trials with phase data)• Click on a phase to view related trials

Phase 1
4 (50.0%)
Phase 2
3 (37.5%)
Phase 3
1 (12.5%)

A 5 Treatment Period Pharmacokinetic Study Evaluating Dose Proportionality and Food Effects of Diazoxide Choline Controlled-Release Tablet (DCCR)

Phase 2
Conditions
Prader-Willi Syndrome
Interventions
First Posted Date
2016-09-08
Last Posted Date
2016-09-09
Lead Sponsor
Essentialis, Inc.
Target Recruit Count
32
Registration Number
NCT02893618

Clinical Study of Diazoxide Choline Controlled-Release Tablet (DCCR) in Patients With Prader-Willi Syndrome

Phase 1
Completed
Conditions
Prader-Willi Syndrome
Interventions
Drug: Placebo
First Posted Date
2014-01-13
Last Posted Date
2016-09-01
Lead Sponsor
Essentialis, Inc.
Target Recruit Count
13
Registration Number
NCT02034071
Locations
🇺🇸

University of California, Irvine, Orange, California, United States

Pharmacokinetic Study of Diazoxide Choline in Hypertriglyeridemic Subjects

Phase 1
Completed
Conditions
Hypertriglyceridmia
Interventions
First Posted Date
2010-09-30
Last Posted Date
2014-01-10
Lead Sponsor
Essentialis, Inc.
Target Recruit Count
9
Registration Number
NCT01211860
Locations
🇺🇸

Cetero, Fargo, North Dakota, United States

Efficacy Study of Diazoxide Choline to Treat Hypertriglyceridemia

Phase 2
Completed
Conditions
Hypertriglyceridemia
Dyslipidemia
Interventions
First Posted Date
2010-09-30
Last Posted Date
2014-01-10
Lead Sponsor
Essentialis, Inc.
Target Recruit Count
44
Registration Number
NCT01211847

Diazoxide Choline Controlled-Release Tablet (DCCR) for Very High Triglycerides

Phase 3
Withdrawn
Conditions
Hypertriglyceridemia
Interventions
Drug: 290 mg DCCR
Drug: 435 mg DCCR
Drug: 135 mg fenofibric acid
Drug: Placebo
First Posted Date
2009-09-09
Last Posted Date
2016-09-01
Lead Sponsor
Essentialis, Inc.
Registration Number
NCT00973271
  • Prev
  • 1
  • 2
  • Next

News

No news found
© Copyright 2025. All Rights Reserved by MedPath